GCP Executive Board - Dr Andy Williams

Vice President Cambridge Strategy- AstraZeneca

Andy works closely with regional and national stakeholders to develop the local infrastructure, promoting the life sciences sector and inspiring the next generation of scientists through AstraZeneca’s extensive local community outreach activities.

With the arrival of AstraZeneca’s strategic R&D Centre and global head office in Cambridge, Andy has been an active contributor to evolving Cambridge’s thinking in areas like transport, skill development, community amenity, housing and digital.

Andy joined MedImmune, formerly Cambridge Antibody Technology (CAT), in 1993 as a Senior Scientist and quickly took on a number of increasingly senior roles within CAT prior to its integration into MedImmune in 2007. These included the leadership of several drug discovery and technology development projects for CAT and also responsibility for strategic management.